Phase 1 study shows novel KRAS inhibitor well tolerated by patients with adenocarcinoma and non-small cell lung cancer
A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according ...
Sep 8, 2019
0
5